The Chairman's Corner

Access limitations for combination treatments: Can RWD and co-creation of new approaches overcome it?


Health Technology Assessment international, Vancouver

A drug which is only authorized in combination with another drug is not combined in pricing, it is much rather added to the base drug. Reimbursement systems are therefore dealing with unmanageable costs for combination therapies. Swiss insurers and other stakeholders are in the midst of negotiating an applicable combination pricing system. However, many questions are still left unanswered.

Presentation (PDF, 384KB)